Archive for the ‘U.S. Food and Drug Administration’ Category
Fuad El-Hibri Announces Emergent BioSolutionsAward to Supply BioThrax Anthrax Vaccine to U.S. Government
Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc.,(NYSE: EBS) announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion. BioThrax is [...]
In: BioDefense, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, BIOTHRAX®, Food and Drug Administration, Fuad El-Hibri
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Healthcare, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Singapore Ministry of Health
Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation
ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, U.S. Food and Drug Administration · Tagged with: anthrax vaccine, Biothrax, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule
ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]
In: Biothrax, Chief Executive Officer, Food and Drug Administration, Fuad El-Hibri, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Strategic National Stockpile
CEO took roundabout path to Emergent
By Marjorie Censer
Monday, January 3, 2011
Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador.
But getting started in his current position as chief executive of Rockville-based pharmaceutical company Emergent BioSolutions took [...]
In: Chief Executive Officer, El-Hibri, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, U.S. Food and Drug Administration, United States, Yale university · Tagged with: Chief executive officer, DEPARTMENT OF HEALTH AND HUMAN SERVICES, El-Hibri, Emergent Biosolutions Inc, entrepreneur, Rockville
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services
Fuad El-Hibri and the International Biomedical Research Alliance
The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]
In: Anthrax vaccines, Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States, Washington D.C · Tagged with: Education, Fuad El-Hibri, Leadership, Medical research, National Institutes of Health, Research, United States
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. government
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
New Contract Valued at up to $28.7 Million for Phase II Clinical Trial
ROCKVILLE, Md., Sep 01, 2010 –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, National Institutes of Health, Research and development
Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility
ROCKVILLE, MD, July 16, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O’Malley and Fuad El-Hibri, Emergent’s chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations Baltimore. Emergent’s [...]
In: Biothrax, Emergent Bioslutions, Fuad El-Hibri, U.S. Food and Drug Administration · Tagged with: Chief executive officer, Emergent BioSolutions, Employment, Fuad El-Hibri, Martin O'Malley, Maryland, United States
